Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 13/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.44 |
| ▸ | OXTR | P30559 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346057 | 0.91 | AVPR2 (0.45) | AVPR2AVPR1AOXTRALDH1A1TSHR | |
| SCHEMBL1345835 | 0.90 | AVPR2 (0.48) | AVPR2AVPR1AOXTRLMNA | |
| SCHEMBL1346629 | 0.86 | AVPR2 (0.45) | AVPR2AVPR1AOXTRALDH1A1TSHR | |
| SCHEMBL1344237 | 0.81 | AVPR2 (0.48) | AVPR2AVPR1AOXTR | |
| SCHEMBL1344169 | 0.80 | AVPR2 (0.64) | AVPR2 | |
| SCHEMBL1346049 | 0.79 | AVPR2 (0.44) | AVPR2AVPR1AOXTR | |
| SCHEMBL1344366 | 0.78 | AVPR2 (0.47) | AVPR2AVPR1AOXTRALDH1A1TSHR | |
| SCHEMBL1346124 | 0.75 | AVPR2 (0.48) | AVPR2AVPR1AOXTR | |
| SCHEMBL1346053 | 0.72 | AVPR2 (0.64) | AVPR2 | |
| SCHEMBL1345832 | 0.69 | AVPR2 (0.60) | AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| EP-1627876-A1 | Heterocyclic condensed compounds useful as antidiuretic agents | FERRING B.V. (NL) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885OXTR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.